Brief: Alterity Therapeutics Enrolls First Patient In The United Kingdom In Ath434 Phase 2 Clinical Trial In Multiple System Atrophy
04/04/2023 13:06
April 4 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS ENROLLS FIRST PATIENT IN THE UNITED
KINGDOM IN ATH434 PHASE 2 CLINICAL TRIAL IN MULTIPLE SYSTEM
ATROPHY
Source text for Eikon: ID:nGNXb87fgK
Further company coverage: ATH.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital